Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
CRISPR Therapeutics AG is a leading biotechnology company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing technology. The company is primarily engaged in advancing its pipeline of therapies targeting genetic diseases, with a notable focus on hemoglobinopathies and oncology, leveraging its strategic partnerships with Vertex Pharmaceuticals and other entities.
CRISPR Therapeutics generates revenue primarily through collaboration agreements with larger pharmaceutical companies, which provide upfront payments, milestone payments, and royalties on future sales. The company's competitive advantage lies in its cutting-edge CRISPR technology, which offers precise and efficient gene editing capabilities, positioning it favorably against traditional gene therapy approaches.
Advancements in clinical trial results for lead programs, particularly CTX001 for sickle cell disease and beta-thalassemia
Partnership developments or expansions with major pharmaceutical companies
Regulatory approvals or setbacks for gene therapies
Market sentiment regarding the broader gene editing landscape
Regulatory changes impacting gene editing technologies could affect approval timelines and market access.
Technological disruption from competing gene editing technologies or alternative therapies.
Emerging competitors in the CRISPR space, such as Editas Medicine and Intellia Therapeutics, could capture market share.
Potential for large pharmaceutical companies to develop in-house capabilities, reducing reliance on CRISPR's technology.
High cash burn rate could deplete resources if clinical trials do not yield positive results.
Limited revenue generation may strain financial flexibility in the long term.
low - The demand for gene therapies is less correlated with economic cycles, as they address specific genetic disorders regardless of broader economic conditions.
Moderate - Rising interest rates could increase the cost of capital, impacting the company's ability to fund R&D initiatives, although the immediate effect may be mitigated by existing cash reserves.
minimal - The company has a manageable debt-to-equity ratio of 0.43, indicating limited reliance on credit.
growth - Investors are likely attracted to the potential for high returns from breakthrough therapies in the gene editing space.
high - The stock has exhibited significant volatility, reflecting the high-risk nature of biotech investments and reliance on clinical trial outcomes.